- Home
- SNGX vs KLTO Comparison
SNGX vs KLTO Comparison
Compare SNGX & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- KLTO
- Stock Information
- Founded
- SNGX 1987
- KLTO 2019
- Country
- SNGX United States
- KLTO United States
- Employees
- SNGX N/A
- KLTO N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- KLTO
- Sector
- SNGX Health Care
- KLTO
- Exchange
- SNGX Nasdaq
- KLTO NYSE
- Market Cap
- SNGX 6.5M
- KLTO 5.9M
- IPO Year
- SNGX 1987
- KLTO N/A
- Fundamental
- Price
- SNGX $1.28
- KLTO $1.34
- Analyst Decision
- SNGX
- KLTO
- Analyst Count
- SNGX 0
- KLTO 0
- Target Price
- SNGX N/A
- KLTO N/A
- AVG Volume (30 Days)
- SNGX 2.7M
- KLTO 22.5M
- Earning Date
- SNGX 08-08-2025
- KLTO 08-15-2025
- Dividend Yield
- SNGX N/A
- KLTO N/A
- EPS Growth
- SNGX N/A
- KLTO N/A
- EPS
- SNGX N/A
- KLTO N/A
- Revenue
- SNGX $2,342.00
- KLTO N/A
- Revenue This Year
- SNGX N/A
- KLTO N/A
- Revenue Next Year
- SNGX N/A
- KLTO N/A
- P/E Ratio
- SNGX N/A
- KLTO N/A
- Revenue Growth
- SNGX N/A
- KLTO N/A
- 52 Week Low
- SNGX $1.09
- KLTO $0.11
- 52 Week High
- SNGX $8.55
- KLTO $3.91
- Technical
- Relative Strength Index (RSI)
- SNGX 34.55
- KLTO N/A
- Support Level
- SNGX $1.09
- KLTO N/A
- Resistance Level
- SNGX $1.88
- KLTO N/A
- Average True Range (ATR)
- SNGX 0.14
- KLTO 0.00
- MACD
- SNGX -0.01
- KLTO 0.00
- Stochastic Oscillator
- SNGX 22.78
- KLTO 0.00
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.